WallStreetZenWallStreetZen

NASDAQ: CSBR
Champions Oncology Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Champions Oncology earnings were $4.7M for the trailing 12 months ending Apr 30, 2025, with N/A growth year over year. The latest CSBR earnings report on Apr 30, 2025 announced Q2 2025 earnings of -$1.8M, down 140.8% from last quarter. For the last reported fiscal year 2025 ending Apr 30, 2025, CSBR reported annual earnings of $4.7M, with -164.6% growth. The next CSBR earnings date is Sep 9, 2025.

CSBR past earnings growth

How has CSBR's earnings growth performed historically?

Company
N/A
Industry
31.2%
Market
29.26%
CSBR's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CSBR's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

CSBR earnings history

Current Revenue
$56.9M
Current Earnings
$4.7M
Current Profit Margin
8.3%

CSBR Return on Equity

Current Company
196.1%
Current Industry
-60.2%
Current Market
31.3%
CSBR's Return on Equity (196.1%)... subscribe to Premium to read more.
High Return on Equity Performance

CSBR undefined

Current Company
16.6%
Current Industry
-2.5%
CSBR is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when CSBR announces earnings.

CSBR undefined

Current Company
54.48%
Current Industry
5.8%
CSBR has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CSBR vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
CSBR$6.27M$4.70M+83.48%$0.34
CELU-$43.55M-$57.89MN/A-$2.64
ORMP-$34.88M-$24.22MN/A-$0.61
ONCY-$22.13M-$22.50MN/A-$0.29
CVM-$20.81M-$25.42MN/A-$9.04
View Top Biotech Stocks

CSBR earnings dates

Next earnings date
Sep 9, 2025

Champions Oncology Earnings Reports & History FAQ

What were Champions Oncology's earnings last quarter?

On CSBR's earnings call on Invalid Date, Champions Oncology (NASDAQ: CSBR) reported Q1 2025 earnings per share (EPS) of -$0.14, up 1,300% year over year. Total CSBR earnings for the quarter were -$1.84 million. In the same quarter last year, Champions Oncology's earnings per share (EPS) was -$0.01.

If you're new to stock investing, here's how to buy Champions Oncology stock.

When does Champions Oncology report earnings?

The next CSBR earnings date is Invalid Date. Add CSBR to your watchlist to be reminded of Champions Oncology's next earnings date.

Is Champions Oncology profitable or losing money?

As of the last Champions Oncology earnings report, Champions Oncology is currently profitable. Champions Oncology's net profit (also called net income) for the twelve months ending Apr 30, 2025 was $4.70 million, a 164.61% decrease year over year.

What was CSBR's earnings growth in the past year?

As of Champions Oncology's earnings date in Invalid Date, Champions Oncology's earnings has grown year over year. CSBR earnings in the past year totalled $4.70 million.

What are Champions Oncology's earnings expectations?

The current EPS estimate for Champions Oncology's earnings report in Invalid Date is $0.06.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.